Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) CEO James F. Oliviero III Sells 9,233 Shares

Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) CEO James F. Oliviero III sold 9,233 shares of the company’s stock in a transaction on Friday, February 7th. The stock was sold at an average price of $3.41, for a total value of $31,484.53. Following the transaction, the chief executive officer now directly owns 3,785,350 shares in the company, valued at approximately $12,908,043.50. The trade was a 0.24 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link.

Checkpoint Therapeutics Price Performance

NASDAQ CKPT opened at $3.13 on Wednesday. The stock’s fifty day moving average price is $3.39 and its 200 day moving average price is $2.99. Checkpoint Therapeutics, Inc. has a 1 year low of $1.38 and a 1 year high of $4.50. The company has a market cap of $152.84 million, a price-to-earnings ratio of -1.70 and a beta of 1.36.

Checkpoint Therapeutics (NASDAQ:CKPT) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($0.23) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.15) by ($0.08). Research analysts expect that Checkpoint Therapeutics, Inc. will post -0.94 earnings per share for the current year.

Wall Street Analyst Weigh In

Several brokerages recently weighed in on CKPT. Lake Street Capital boosted their target price on Checkpoint Therapeutics from $4.00 to $7.00 and gave the stock a “buy” rating in a research note on Monday, December 16th. HC Wainwright restated a “buy” rating and set a $20.00 price objective on shares of Checkpoint Therapeutics in a report on Monday, December 16th. Finally, D. Boral Capital began coverage on shares of Checkpoint Therapeutics in a research note on Monday, January 13th. They issued a “buy” rating and a $9.00 target price for the company.

Hedge Funds Weigh In On Checkpoint Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the business. Virtu Financial LLC lifted its stake in Checkpoint Therapeutics by 180.5% during the 4th quarter. Virtu Financial LLC now owns 38,157 shares of the company’s stock valued at $122,000 after acquiring an additional 24,552 shares during the period. Raymond James Financial Inc. purchased a new position in shares of Checkpoint Therapeutics during the fourth quarter worth $67,000. Charles Schwab Investment Management Inc. acquired a new position in Checkpoint Therapeutics during the fourth quarter valued at $64,000. SBI Securities Co. Ltd. purchased a new stake in Checkpoint Therapeutics in the fourth quarter valued at $32,000. Finally, PUREfi Wealth LLC acquired a new stake in Checkpoint Therapeutics during the 4th quarter worth about $32,000. Institutional investors and hedge funds own 22.00% of the company’s stock.

About Checkpoint Therapeutics

Checkpoint Therapeutics, Inc, a clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers in the United States and internationally. The company's lead antibody product candidate is Cosibelimab, which is in Phase 1 clinical trial to treat patients with selected recurrent or metastatic cancers; and CK-302, a product candidate in preclinical trials for hematological malignancies and solid tumors.